BTW: they are finally starting to communicate like a 'growth stock'.
Ahead of major anns like EMA P2B approvals and FDA orphan drug applications, don't be surprised if we receive some goodies from the lab to drive momentum.
This 'next steps' statement from may ann is very interesting - I'm expecting more data to be shared soon:
___________________________________
As ANP continues to prepare for a Phase IIb, the Company will look to gain a deeper understanding of the drug's effects. This activity is likely to include further laboratory analysis of retained serum to attempt to tease out more insight on broader inflammatory processes and a deeper analysis of our data against the natural history of the disease with key experts.
- Forums
- ASX - By Stock
- PER
- Prof Thomas Voit, DMD expert, interview with Wilsons advisory
Prof Thomas Voit, DMD expert, interview with Wilsons advisory, page-31
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.9¢ |
Change
-0.002(2.47%) |
Mkt cap ! $81.90M |
Open | High | Low | Value | Volume |
8.0¢ | 8.1¢ | 7.8¢ | $1.034M | 12.98M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 349999 | 7.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.0¢ | 305419 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 349999 | 0.079 |
13 | 925066 | 0.078 |
11 | 938445 | 0.077 |
6 | 776200 | 0.076 |
12 | 1232581 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.080 | 305419 | 1 |
0.081 | 550144 | 3 |
0.082 | 599880 | 3 |
0.084 | 400000 | 1 |
0.085 | 40000 | 1 |
Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |